Semaglutide vs Tirzepatide.
Both are weekly GLP-1 injections that produce serious weight loss. Tirzepatide is the newer, more aggressive tool — but semaglutide is still the right answer for plenty of people. Here's the honest comparison.
Same family, same fundamentals.
Both are weekly subcutaneous injections that mimic the gut hormone GLP-1. Both slow gastric emptying, suppress appetite via signaling to the brainstem, and improve insulin sensitivity. Both produce clinically significant weight loss far beyond what diet and exercise alone deliver.
Both share the same titration ethos: start low, ramp every four weeks, never skip dose tiers. The mechanism that drives the weight loss is the same mechanism that drives the GI side effects, so gradual escalation is the only honest way to manage tolerability.
The differences that actually matter.
The headline difference: tirzepatide is a dual agonist. It hits the GLP-1 receptor the same way semaglutide does, but it also activates GIP receptors. GIP on its own does very little for body weight, but stacked with GLP-1 it produces a synergistic effect on satiety and metabolic rate. The result is roughly 50% more weight loss at peak doses in head-to-head trials.
Side effect profiles overlap but diverge in pattern. Nausea is the dominant complaint on both. Tirzepatide users sometimes report slightly worse early-onset GI effects in weeks 1–2 but better tolerance at maintenance — the GIP arm appears to dampen long-run GI signaling. Constipation is more common on tirzepatide; diarrhea is more common on semaglutide.
Pricing tilts toward semaglutide if you're going through insurance for diabetes (Ozempic is widely covered) but tilts toward tirzepatide for direct-purchase obesity treatment (Zepbound's compounded price has fallen faster than Wegovy's). In the research-peptide market, tirzepatide is typically priced 1.5–2× per mg, though the smaller effective dose narrows the real-world gap.
Which one fits your goal.
If you're new to GLP-1s, semaglutide is the conservative start. Plenty of clinical data across millions of patient-years, well-characterized side effect profile, smaller microgram doses give you room to test your reaction. The downside is a lower ceiling — average loss tops out around 15% even at maximum dose.
If you're plateauing on semaglutide at max dose, tirzepatide is the natural step up — same family, more horsepower. If pure weight loss is the goal and side effects are manageable, tirzepatide is the answer in 2026.
Both work. The pick comes down to your starting point, tolerability, and how aggressive you want to be. Many users start on semaglutide, hit a plateau, and graduate to tirzepatide — that's a defensible path.
Reconstitute either one in seconds.
Common questions.
Can I switch from semaglutide to tirzepatide directly?+
Yes, but step the dose down. Reasonable bridge: stop semaglutide on your last weekly day, then start tirzepatide 7 days later at 2.5 mg/week regardless of where you were on the semaglutide curve. Re-titrate up the standard schedule from there.
Which has worse side effects?+
Nausea is roughly dose-equivalent across the two at peak. Tirzepatide tends to have a tougher first 2 weeks but smoother maintenance. The honest answer: there's no consistent winner — it depends on your gut.
Why does tirzepatide produce more weight loss?+
GIP receptor activation adds an axis: glucose-dependent insulin response, reduced glucagon secretion, and a small bump in energy expenditure. None of these are huge alone, but stacked on GLP-1 agonism they compound.